Skip to main content

Table 4 Analysis of the risk factors of neonatal hypoglycemia in the RD intravenous administration group

From: Incidence and risk factors of neonatal hypoglycemia after ritodrine therapy in premature labor: a retrospective cohort study

  No Neonatal Hypoglycemia Neonatal Hypoglycemia P value AOR 95%CI P value
Cases (n) 36 (38.3) 58 (61.7)     
Maternal age over 35 (n) 7 (19.4) 24 (41.4) 0.042 3.385 1.082–10.588 0.036
Maternal height (cm) 158.5 (140.0 – 169.0) 158.0 (146.0 – 174.0) 0.703    
Pre-pregnancy BMI (kg/m2) 20.4 (15.3 – 26.6) 20.3 (17.0 – 33.8) 0.876    
Maternal weight gain (kg) 8.0 (1.5 – 18.0) 9.0 (3.0 – 17.5) 0.117    
Gestational age (wk/day) 37 /1 (36/0 – 38/4) 37/0 (36/0 – 37/6) 0.598    
Birth weight < 2500 g (n) 7 (19.4) 26 (44.8) 0.015 2.479 0.774–7.942 0.126
Twin birth (n) 6 (16.7) 25 (43.1) 0.012 2.417 0.743–7.863 0.143
Administration of magnesium sulfate (n) 4 (11.1) 11 (19.0) 0.393    
Administration length (day) 43.5 (0.04 – 134.0) 38.5 (6.0 – 147.0) 0.694    
Final administration dose rate (μg/min) 65.0 (33.0 – 192.3) 93.3 (32.1 – 192.3) 0.048 0.999 0.987–1.011 0.878
Interval (hr) 12.5 (0.0 – 154.0) 1.3 (0.0 – 167.9) < 0.001 0.974 0.953–0.996 0.020
  1. Data are expressed as median (min-max) or number (%). The final administration dose rate is that at the time of stopping maternal intravenous administration of RD. The interval is the time period from stopping maternal intravenous administration of RD to delivery
  2. RD: ritodrine hydrochloride, AOR adjusted odds ratio, CI confidence interval